Cardiogen
AEDR peptide, Ala-Glu-Asp-Arg, cardiac bioregulator peptide
Cardiogen is marketed as a heart-specific peptide bioregulator from the Khavinson series. The AEDR peptide itself does appear in a small number of published biophysical and computational studies, but no study in any species has examined it in cardiac tissue or measured any cardiac outcome. Every claim made for it about the heart is an extrapolation from the general theory of the series.
Mechanism
No cardiac mechanism has been demonstrated for AEDR. What is offered instead is the generic Khavinson model applied by analogy: short peptides enter the nucleus, bind promoter DNA or histone tails in a sequence-selective manner, and thereby regulate transcription in a tissue-specific way, with each peptide supposedly matched to one organ. In this framing Cardiogen is assigned to cardiomyocytes, and vendors describe effects on cardiomyocyte apoptosis, fibroblast proliferation and cytoskeletal protein expression.
There is a thin experimental thread that mentions AEDR, but it concerns generic macromolecular binding rather than cardiac biology. A 2013 fluorescence-quenching study reported that AEDR, along with five other short peptides from the series, binds FITC-labelled wheat histones H1, H2B, H3 and H4 and their complexes with deoxyribo-oligonucleotides. Wheat histones are a long way from cardiomyocytes, and the authors themselves note that no homologous sequences were found in wheat core histones, so the binding is attributed to conformation rather than sequence recognition. A 2023 computational study from the same group listed AEDR among peptides predicted to be efficient ligands of the LAT and PEPT membrane transporters.
The tissue-specificity premise deserves direct scrutiny. The general Khavinson work reports that different short peptides produce differing effects in organotypic cultures of different tissues, but no mechanistic account has ever been established of how a four-residue sequence achieves organ-selective gene targeting. Four amino acids carry very little information, and there is no structural biology showing selective recognition of a cardiac promoter element by AEDR or by any peptide in the series.
What the research shows
At the level that matters for the marketing claim, there is nothing. We could not identify a single published in vitro, animal, pharmacokinetic, toxicological or clinical study examining this peptide in cardiac tissue or measuring any cardiac endpoint. Searching PubMed for 'cardiogen' as a title term returns records concerned with cardiogenic shock, cardiogenic pulmonary oedema, cardiogenesis, a Hungarian cardiomyopathy registry and a rubidium-82 infusion system, none of which concern this peptide.
What does exist is narrow and non-cardiac. AEDR appears as one item in a panel of six short peptides in a 2013 study of binding to plant histones, and among 26 ultrashort peptides in a 2023 in silico docking study of amino acid and peptide transporters. Neither examines heart cells, heart tissue, or any physiological cardiac outcome, and neither is a study of Cardiogen as a product. There is no registered clinical trial, no human data, no animal data and no toxicology.
This matters more than a simple gap in a literature review. Cardiogen is sold to consumers who are frequently older and often have cardiovascular disease, on the basis of claims about cardiomyocyte protection and cardiac recovery that have no experimental support whatsoever. Where a marketed compound has no evidence relevant to the organ it is sold for, the appropriate statement is not that evidence is 'emerging' or 'preliminary' but that it does not exist.
Evidence assessment
Preclinical only
The only indexed work touching this peptide is a plant-histone binding assay and an in silico transporter docking study; nothing has been measured in cardiac tissue in any species, and there is no animal, human or toxicological data.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides Preclinical only
AEDR, alongside AEDG, EDR, AEDL, KEDG and KEDW, quenched labelled wheat histone fluorescence in a manner dependent on peptide and oligonucleotide primary structure.
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters Preclinical only
AEDR was among the ultrashort peptides predicted to bind these transporters efficiently, leading the authors to propose transporter-mediated cellular uptake.
Peptides tissue-specifically stimulate cell differentiation during their aging Preclinical only
Reported that different short peptides preferentially stimulate differentiation in cultures of the tissue they are nominally matched to.
The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats Preclinical only
Reported tissue-selective effects of several synthetic short peptides on explant growth.
Safety
Entirely uncharacterised. No toxicology, no animal safety study, no human exposure data. The specific concern with this compound is the population it is marketed to: people with existing cardiac disease, who may substitute or delay evidence-based cardiovascular treatment that has demonstrated mortality benefit. Material sold online is unregulated, and no published analytical reference standard exists for identity checking.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, and absent from all clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
None on the heart. The AEDR peptide appears in a 2013 study of binding to wheat histones and in a 2023 computer-modelling study of membrane transporters, but no study in any species has examined it in cardiac cells, cardiac tissue, or measured any cardiac outcome. A PubMed search for 'cardiogen' returns papers about cardiogenic shock and a rubidium infusion system, which are unrelated.
There is no experimental evidence for this. Claims about cardiomyocyte apoptosis, fibroblast proliferation and cardiac recovery appear in commercial descriptions but do not trace to any published experiment on this peptide in heart tissue.
The Khavinson model assigns each short peptide to one organ, and Cardiogen is assigned to the heart. How a four-residue peptide would achieve organ-selective gene targeting has never been demonstrated; four amino acids carry very little sequence information, and the one binding study involving AEDR used wheat histones.
Unknown, and that uncertainty is the point. There is no toxicology and no human data. The greater risk for someone with cardiovascular disease may be substituting an unevidenced compound for treatments that do have proven mortality benefit.